Aventis has bought itself up to three months' respite from the €48bn ($59bn) hostile bid from Sanofi-Synthélabo by resorting to the French legal system.

The Paris appeals court will hear two cases linked to the bid on May 6 against the Autorité des Marchés Financiers (AMF), France's financial regulator.